Altimmune inks deal to acquire Spitfire Pharma and its NASH candidate

Altimmune inks deal to acquire Spitfire Pharma and its NASH candidate

Published: 15 hours ago By Saif Ali Bepari

Altimmune, Inc., a clinical stage biopharma company, has recently confirmed the closing of a formerly announced acquisition of Spitfire Pharma, Inc., including the strong GLP-1/Glucagon receptor co-agonist product candidate ALT-801 for trea....

Sun Pharma launches lipid disorders drug Ezallor Sprinkle™ in the U.S.

Ezallor Sprinkle™ (rosuvastatin) capsules can be indicated for three lipid disorders in conjunction with patient’s diet. Indian pharma giant, Sun Pharmaceutical Industries Ltd. has recently announced the U.S. launch of Ezallor ....

MacroGenics, I-Mab team up to develop & market enoblituzumab in China

MacroGenics, Inc. and I-Mab Biopharma, a U.S. and China based clinical-stage biopharmaceutical company that is committed to discover and develop biologics in autoimmune and immune-oncology diseases, have recently announced that they have in....

ViiV Healthcare announces positive result in TANGO Phase 3 study

ViiV Healthcare Limited, a pharmaceutical company specializing in HIV treatment, recently announced positive results from Phase 3 TANGO study. The study was conducted to assess viral suppression in adults with HIV1 with a 2 drug regimen of....

Compass Therapeutics announces first-in-human Phase 1 trial of CTX-471

CTX-471 has shown promising preclinical data, which include total eradication of established tumors in syngeneic mouse models. Compass Therapeutics, a clinical-stage biopharmaceutical firm targeting human immune synapse with novel monoclon....

Skyhawk Therapeutics expands licensing partnership with Biogen

Skyhawk Therapeutics, Inc. has recently announced the expansion of its partnership with Biogen, which was initially announced on January 4, 2019. The expansion, which leverages on the breadth of SkySTAR™ technology platform from Skyh....

Priority review granted to BeiGene’s Tislelizumab in China by NMPA

BeiGene, Co., Ltd., a commercial-stage biotechnology company recently announced that China NMPA (National Medical Products Administration) has granted priority review status to the sNDA (supplemental new drug application) for an investigati....

Industry Updates